LitAlert ~~ GeneLit.com

    • Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer.
    • Corso G, Girardi A, Calvello M, Gandini S, Gaeta A, Marabelli M, Magnoni F, Veronesi P, Guerrieri-Gonzaga A, Bonanni B.
    • Breast Cancer Res Treat. 2022 Nov 4. doi: 10.1007/s10549-022-06776-0. Epub ahead of print.

    • A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia.
    • Powell M, Fuller S, Gunderson E, Benz C.
    • Breast Cancer Res Treat. 2022 Nov 4. doi: 10.1007/s10549-022-06789-9. Epub ahead of print.

    • Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.
    • Han H, Park CK, Cho NH, Lee J, Jang WS, Ham WS, Choi YD, Cho KS.
    • Int J Mol Sci. 2022 Nov 3;23(21):13426. doi: 10.3390/ijms232113426.

    • Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition.
    • Hughes E, Wagner S, Pruss D, Bernhisel R, Probst B, Abkevich V, Simmons T, Hullinger B, Judkins T, Rosenthal E, Roa B, Domchek SM, Eng C, Garber J, Gary M, Klemp J, Mukherjee S, Offit K, Olopade OI, Vijai J, Weitzel JN, Whitworth P, Yehia L, Gordon O, Pederson H, Kurian A, Slavin TP, Gutin A, Lanchbury JS.
    • JCO Precis Oncol. [2022 Nov 3];6:e2200084. doi: 10.1200/PO.22.00084.

    • Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP.
    • Adv Ther. 2022 Oct 28. doi: 10.1007/s12325-022-02302-2. Epub ahead of print.